NanoSight, leading manufacturers of unique
nanoparticle characterization technology, announces the appointment of renowned
UK scientist and former government advisor, Dr Andrew Shuttleworth, as Director
of Diagnostic Sciences.
NanoSight welcomes Dr Andrew Shuttleworth to the board of the company in the
capacity of Director of Diagnostic Sciences. Dr Shuttleworth's appointment
further strengthens the scientific team. His experience will greatly add to
NanoSight's position as the UK's fastest growing Biotechnology company.*
Andrew Shuttleworth brings a wealth of scientific knowledge to the rapidly
expanding NanoSight organization. Having been awarded degrees in in applied
biological sciences and virology, he spent twenty years at Porton Down research
establishments involved in both fundamental research in microbiology and
immunology, and the application of that research to medical and defense issues;
particularly the rapid identification of select biological agents. This led to
a leading role in the development of the UK's first practical biological agent
detection system, fielded during the Gulf War in 1991, and acted as the
scientific liaison on chemical and biological issues with UK and US Forces
throughout the Gulf region. Andrew returned to Porton Down where he directed a
team of analytical chemists, microbiologists and operational analysts providing
chemical and biological risk and threat assessments. He also provided real-time
operational advice and support to the Ministry of Defence, the Home Office and
other government departments. In 2001, Andrew took up an appointment with the
UK Foreign & Commonwealth Office to provide scientific advice and expertise
on a diverse range of topics of national interest.
CEO Jeremy Warren says "Our growing involvement in characterization of
exosomes and microvesicles has been driven by users. Increasingly we are
recognizing major potential in exosome diagnostics, so the fit with Andrew is
remarkable. He has followed development of NanoSight's technology since we
began and been an advisor to some of our shareholders plus he has a depth of
diagnostics experience. This appointment is as obvious as it is attractive for
all parties."
Andrew Shuttleworth comments: "The emerging field of exosomes and
nanovesicles now looks set to give rise to a fundamental shift in the way in
which disease is detected, diagnosed and monitored. Currently, it is a growing
research field, which NanoSight is exploiting fully through the provision of
increasingly capable research instrumentation. Eventually, multiple biomarkers
will be identified for each relevant disease state and this will drive the development
of new analytical capabilities. Whilst it is too early to suggest that
NanoSight technology will supplant existing capabilities (e.g. ELISA, qPCR), it
would be prudent to recognize that NanoSight has the potential to do so -
particularly where multiple-parameter tests and quantitative results might be
desirable. NanoSight also has the potential to assist in the development of
other novel assay systems that might be needed to fully exploit the potential
benefits of exosomes and nanovesicles."
To find out about the company and to learn more about particle characterization
using NanoSight's unique nanoparticle tracking analysis solutions, visit
www.nanosight.com
and register to receive the next issue of NanoTrail, the company's electronic
newsletter.
*NanoSight was named the UK fastest growing biotechnology company in 2011 by
Deloitte in their annual Technology Fast 50 rankings.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.